很遺憾，我們無法支援你的瀏覽器。如果可以，請升級到新版本，或使用 Mozilla Firefox、Microsoft Edge、Google Chrome 或 Safari 14 或更新版本。如果無法升級，而且需要支援，請將你的回饋寄給我們。
我們衷心感謝你對這個新體驗的回饋。告訴我們你的想法 打開新的分頁／視窗
In this segment we focus on corporate researchers' attitudes toward AI, including generative AI (GenAI), we cover its attractiveness, perceived impact, the benefits to them and wider society, the degree of transparency necessary to be comfortable using tools that capitalize on the technology, and the challenges they see with AI.
Between December 2023 and February 2024, independent market research firm Ipsos conducted interviews with more than 3,000 people globally working in academia and healthcare. The findings for corporate researchers begin here:
38% of respondents have already used AI for work purposes
76% expect to use AI within the next 2-5 years
96% think AI will accelerate knowledge discovery
Almost all respondents think AI will drive knowledge discovery in their field, and 71% say the impact will be transformative or significant. Most respondents also believe AI will realize cost savings for businesses (93%) and free up their time to focus on higher value projects (85%). For researchers who believe AI can benefit their areas of work, 98% say they are likely to use it to generate syntheses of research articles and 93% are likely to use it to identify gaps in knowledge and generate new research hypotheses.
At Elsevier, we work with the academic, research and health communities to combine trusted, verified content and human expertise with the power of AI to advance human progress.
We are committed to maintaining the quality and integrity of scientific and medical information amidst the rapid growth of data and misinformation. Our AI tools are grounded in peer-reviewed articles, medical books, and evidence-based clinical overviews, ensuring accurate and reliable information.
Across industry, R&D leaders are exploring how artificial intelligence (AI) can reinvent scientific research. Visit our industry hub for more information, resources and current events.
